Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Assessment of Cardiac Function and Anesthesia Depth in Patients Undergoing Cardiac Surgery (SHAPE)

18 agosto 2026 aggiornato da: Christos Mantzios, AHEPA University Hospital

Multifactorial Assessment of Cardiac Function Through Deformation Imaging, Hemodynamic Parameters, and Anesthesia-related Variables in Patients Undergoing Cardiac Surgery: The SHAPE Study

The SHAPE study is a prospective, randomized study evaluating changes in cardiac function in adult patients undergoing cardiac surgery with cardiopulmonary bypass. The study focuses on how cardiac function changes during surgery and whether the depth of anesthesia may influence these changes.

Participants are randomly assigned to one of two levels of anesthesia depth, guided by the Bispectral Index (BIS). Cardiac function is assessed using transthoracic echocardiography, including myocardial deformation (strain) imaging and myocardial work measurements. Invasive hemodynamic measurements obtained during surgery are also recorded.

The primary objective is to assess the change in left ventricular global longitudinal strain (LV GLS) between two intraoperative time points: after induction of anesthesia and before cardiopulmonary bypass, and after separation from cardiopulmonary bypass. The study will also examine whether these changes differ according to the assigned depth of anesthesia and whether echocardiographic and hemodynamic measurements are associated with postoperative outcomes.

Participants will also undergo follow-up echocardiographic assessment at 3, 6, and 12 months after surgery to evaluate longer-term changes in cardiac function.

Panoramica dello studio

Stato

Stato

Indica lo stato di reclutamento attuale o lo stato di accesso ampliato.
Reclutamento

Condizioni

Condizioni

La malattia, il disturbo, la sindrome, la malattia o la lesione oggetto di studio. Su ClinicalTrials.gov, le condizioni possono includere anche altri problemi relativi alla salute, come la durata della vita, la qualità della vita e i rischi per la salute.

Intervento / Trattamento

Intervento / Trattamento

Un processo o un'azione che è al centro di uno studio clinico. Gli interventi includono farmaci, dispositivi medici, procedure, vaccini e altri prodotti sperimentali o già disponibili. Gli interventi possono anche includere approcci non invasivi, come l'educazione o la modifica della dieta e dell'esercizio fisico.

Descrizione dettagliata

The SHAPE study is a prospective, randomized, parallel-group, single-masked interventional study conducted in adult patients undergoing elective cardiac surgery with cardiopulmonary bypass. The study is designed to investigate perioperative changes in myocardial function and to assess the potential influence of anesthesia depth on these changes.

Participants are randomized in a 1:1 ratio to two Bispectral Index (BIS)-guided anesthesia strategies: a BIS target of 45-55, representing standard anesthesia depth, or a BIS target of 30-35, representing deeper anesthesia. Total intravenous anesthesia with propofol and remifentanil is adjusted by the treating anesthesiologist to maintain the assigned BIS range. The echocardiographic outcome assessor remains blinded to treatment allocation during image acquisition, offline echocardiographic analysis, and primary outcome assessment.

Cardiac function is evaluated using transthoracic echocardiography and speckle-tracking analysis. Measurements include left ventricular global longitudinal strain (LV GLS), myocardial work indices, and additional indices of left- and right-sided cardiac function. Invasive hemodynamic monitoring using a Swan-Ganz catheter provides measurements including pulmonary capillary wedge pressure, cardiac output, cardiac index, pulmonary artery pressure, and right atrial pressure.

The primary analysis evaluates the within-participant change in LV GLS between two predefined intraoperative time points: after induction of anesthesia and before initiation of cardiopulmonary bypass (T1), and after separation from cardiopulmonary bypass (T2). Secondary analyses will assess whether the magnitude of perioperative changes in LV GLS and myocardial work differs between the two randomized BIS groups and will explore associations between echocardiographic measurements, invasive hemodynamic parameters, and postoperative clinical outcomes.

Postoperative outcomes include low cardiac output syndrome, requirement for inotropic or vasopressor support, postoperative atrial fibrillation, duration of mechanical ventilation, and length of intensive care unit stay. Echocardiographic follow-up is performed at 3, 6, and 12 months after surgery to assess longer-term changes in cardiac function.

Tipo di studio

Tipo di studio

Descrive la natura di uno studio clinico. I tipi di studio includono studi interventistici (chiamati anche studi clinici), studi osservazionali (compresi i registri dei pazienti) e accesso allargato.
Interventistico

Iscrizione (Stimato)

Iscrizione

Il numero di partecipanti a uno studio clinico. L'iscrizione "anticipata" è il numero target di partecipanti di cui i ricercatori hanno bisogno per lo studio.
70

Fase

Fase

La fase di una sperimentazione clinica che studia un farmaco o un prodotto biologico, sulla base delle definizioni sviluppate dalla Food and Drug Administration (FDA) statunitense. La fase si basa sull'obiettivo dello studio, sul numero di partecipanti e su altre caratteristiche. Ci sono cinque fasi: Early Phase 1 (precedentemente indicata come Fase 0), Phase 1, Phase 2, Phase 3 e Phase 4. Not Applicable è usato per descrivere sperimentazioni senza fasi definite dalla FDA, incluse sperimentazioni di dispositivi o interventi comportamentali.
  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Contatto studio

Il nome e le informazioni di contatto della persona che può rispondere alle domande di iscrizione per uno studio clinico. Ogni sede in cui viene condotto lo studio può anche avere un contatto specifico, che potrebbe essere maggiormente in grado di rispondere a tali domande.

Luoghi di studio

  • Grecia
      • Thessaloniki, Grecia, 54636
        • Reclutamento
        • AHEPA University General Hospital of Thessaloniki
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Christos Mantzios, Cardiology Resident, MD, MSc
        • Sub-investigatore:
          • Vasileos Kamperidis, Assistant Professor
        • Sub-investigatore:
          • Despoina Sarridou, Associate Professor

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Criteri di ammissibilità

I requisiti chiave che devono soddisfare le persone che vogliono partecipare a uno studio clinico o le caratteristiche che devono avere. I criteri di ammissibilità sono costituiti sia da criteri di inclusione (necessari a una persona per partecipare allo studio) sia da criteri di esclusione (che impediscono a una persona di partecipare). I tipi di criteri di ammissibilità includono se uno studio accetta volontari sani, ha requisiti di età o gruppo di età o è limitato dal sesso.

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Adults aged 18 years or older, irrespective of sex.
  • Scheduled to undergo elective cardiac surgery involving cardiopulmonary bypass (on-pump surgery).
  • Anticipated adequate acoustic window for transthoracic echocardiography.
  • Provision of written informed consent.

Exclusion Criteria:

  • - Emergency or unscheduled cardiac surgery.
  • Cardiac surgery without cardiopulmonary bypass (off-pump surgery).
  • Refusal or inability to provide written informed consent.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm

Gruppo di partecipanti / Arm

Un gruppo o sottogruppo di partecipanti a uno studio clinico che riceve un intervento/trattamento specifico o nessun intervento, secondo il protocollo dello studio.
Intervento / Trattamento

Intervento / Trattamento

Un processo o un'azione che è al centro di uno studio clinico. Gli interventi includono farmaci, dispositivi medici, procedure, vaccini e altri prodotti sperimentali o già disponibili. Gli interventi possono anche includere approcci non invasivi, come l'educazione o la modifica della dieta e dell'esercizio fisico.
Comparatore attivo: BIS 45-55
Participants assigned to this arm will receive total intravenous anesthesia with propofol and remifentanil, adjusted by the treating anesthesiologist to maintain a Bispectral Index (BIS) target range of 45-55, representing standard anesthesia depth.
Altro: BIS-guided anesthesia: BIS 45-55
Total intravenous anesthesia with propofol and remifentanil will be adjusted by the treating anesthesiologist to maintain a Bispectral Index (BIS) target range of 45-55, representing standard anesthesia depth.
Sperimentale: BIS 30-35
Participants assigned to this arm will receive total intravenous anesthesia with propofol and remifentanil, adjusted by the treating anesthesiologist to maintain a Bispectral Index (BIS) target range of 30-35, representing deeper anesthesia.
Altro: BIS-guided anesthesia: BIS 30-35
Total intravenous anesthesia with propofol and remifentanil will be adjusted by the treating anesthesiologist to maintain a Bispectral Index (BIS) target range of 30-35, representing deeper anesthesia.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misure di risultato primarie

Nel protocollo di uno studio clinico, la misura dell'esito pianificato più importante per valutare l'effetto di un intervento/trattamento. La maggior parte degli studi clinici ha una misura di esito primaria, ma alcuni ne hanno più di una.
Misura del risultato
Misura Descrizione
Lasso di tempo
Within-Participant Change in Left Ventricular Global Longitudinal Strain (LV GLS) From T1 to T2
Lasso di tempo: During index cardiac surgery: T1 after induction of anesthesia and before cardiopulmonary bypass; T2 after separation from cardiopulmonary bypass.
Left ventricular global longitudinal strain (LV GLS) will be assessed by speckle-tracking echocardiography at two predefined intraoperative time points: T1, after induction of anesthesia and before initiation of cardiopulmonary bypass, and T2, after separation from cardiopulmonary bypass. The primary outcome will be the within-participant change in LV GLS, calculated as T2 minus T1 and expressed in percentage points. Because LV GLS is expressed as a negative value, a positive T2-minus-T1 difference indicates a reduction in the absolute magnitude of LV GLS and therefore deterioration in longitudinal systolic function.
During index cardiac surgery: T1 after induction of anesthesia and before cardiopulmonary bypass; T2 after separation from cardiopulmonary bypass.

Misure di risultato secondarie

Misure di risultato secondarie

Nel protocollo di uno studio clinico, una misura dell'esito pianificato che non è importante quanto la misura dell'esito primario per valutare l'effetto di un intervento ma è comunque di interesse. La maggior parte degli studi clinici ha più di una misura di esito secondaria.
Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Left Ventricular Global Longitudinal Strain (LV GLS) From T1 to T2 by Randomized BIS Group
Lasso di tempo: During index cardiac surgery: from T1 before cardiopulmonary bypass to T2 after separation from cardiopulmonary bypass.
Left ventricular global longitudinal strain (LV GLS) will be assessed by speckle-tracking echocardiography at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass. The within-participant change in LV GLS (T2 minus T1), expressed in percentage points, will be compared between participants randomized to the BIS 45-55 and BIS 30-35 groups.
During index cardiac surgery: from T1 before cardiopulmonary bypass to T2 after separation from cardiopulmonary bypass.
Change in Left Ventricular Myocardial Work Indices From T1 to T2 by Randomized BIS Group
Lasso di tempo: During index cardiac surgery: from T1, before cardiopulmonary bypass, to T2, after separation from cardiopulmonary bypass.
Left ventricular myocardial work will be assessed using non-invasive pressure-strain loops at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass. Myocardial work indices will include Global Work Index (GWI), Global Constructive Work (GCW), Global Wasted Work (GWW), and Global Work Efficiency (GWE). Changes from T1 to T2 will be assessed within participants and compared between the BIS 45-55 and BIS 30-35 groups.
During index cardiac surgery: from T1, before cardiopulmonary bypass, to T2, after separation from cardiopulmonary bypass.
Postoperative Adverse Clinical Events
Lasso di tempo: From completion of index cardiac surgery through discharge during the index hospitalization, assessed up to 60 days after surgery.
Postoperative adverse clinical events will include the occurrence of low cardiac output syndrome (LCOS), requirement for inotropic or vasopressor support, and postoperative atrial fibrillation (POAF). Each event will be recorded during the postoperative hospitalization and evaluated in relation to perioperative echocardiographic, hemodynamic, and anesthesia-related parameters.
From completion of index cardiac surgery through discharge during the index hospitalization, assessed up to 60 days after surgery.
Duration of Mechanical Ventilation
Lasso di tempo: From completion of index cardiac surgery until successful extubation during the index hospitalization, assessed up to 60 days after surgery.
The duration of postoperative mechanical ventilation will be recorded as the time from completion of index cardiac surgery until successful extubation. Duration will be expressed in minutes and analyzed in relation to perioperative echocardiographic, hemodynamic, and anesthesia-related parameters.
From completion of index cardiac surgery until successful extubation during the index hospitalization, assessed up to 60 days after surgery.
Length of Intensive Care Unit Stay
Lasso di tempo: From postoperative ICU admission until ICU discharge during the index hospitalization, assessed up to 60 days after surgery.
The length of stay in the intensive care unit (ICU) will be recorded as the duration from postoperative admission to the ICU until discharge from the ICU. Duration will be expressed in days and analyzed in relation to perioperative echocardiographic, hemodynamic, and anesthesia-related parameters.
From postoperative ICU admission until ICU discharge during the index hospitalization, assessed up to 60 days after surgery.
Change in Left Ventricular Global Longitudinal Strain During Follow-up
Lasso di tempo: Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Left ventricular global longitudinal strain (LV GLS) will be assessed by speckle-tracking transthoracic echocardiography and expressed as a percentage (%). LV GLS will be measured preoperatively and reassessed at 3, 6, and 12 months after cardiac surgery. Changes at each follow-up time point will be evaluated relative to the preoperative baseline value.
Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Change in Left Ventricular Global Work Index During Follow-up
Lasso di tempo: Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Left ventricular Global Work Index (GWI) will be assessed using non-invasive pressure-strain loop analysis and expressed in mmHg%. GWI will be measured preoperatively and reassessed at 3, 6, and 12 months after cardiac surgery. Changes at each follow-up time point will be evaluated relative to the preoperative baseline value.
Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Change in Left Ventricular Global Constructive Work During Follow-up
Lasso di tempo: Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Left ventricular Global Constructive Work (GCW) will be assessed using non-invasive pressure-strain loop analysis and expressed in mmHg%. GCW will be measured preoperatively and reassessed at 3, 6, and 12 months after cardiac surgery. Changes at each follow-up time point will be evaluated relative to the preoperative baseline value.
Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Change in Left Ventricular Global Wasted Work During Follow-up
Lasso di tempo: Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Left ventricular Global Wasted Work (GWW) will be assessed using non-invasive pressure-strain loop analysis and expressed in mmHg%. GWW will be measured preoperatively and reassessed at 3, 6, and 12 months after cardiac surgery. Changes at each follow-up time point will be evaluated relative to the preoperative baseline value.
Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Change in Left Ventricular Global Work Efficiency During Follow-up
Lasso di tempo: Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Left ventricular Global Work Efficiency (GWE) will be assessed using non-invasive pressure-strain loop analysis and expressed as a percentage (%). GWE will be measured preoperatively and reassessed at 3, 6, and 12 months after cardiac surgery. Changes at each follow-up time point will be evaluated relative to the preoperative baseline value.
Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Change in Right Ventricular Free-Wall Strain During Follow-up
Lasso di tempo: Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Right ventricular free-wall strain (RV FWS) will be assessed by speckle-tracking transthoracic echocardiography and expressed as a percentage (%). RV FWS will be measured preoperatively and reassessed at 3, 6, and 12 months after cardiac surgery. Changes at each follow-up time point will be evaluated relative to the preoperative baseline value.
Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Change in Right Atrial Strain During Follow-up
Lasso di tempo: Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Right atrial strain (RA strain) will be assessed by speckle-tracking transthoracic echocardiography and expressed as a percentage (%). RA strain will be measured preoperatively and reassessed at 3, 6, and 12 months after cardiac surgery. Changes at each follow-up time point will be evaluated relative to the preoperative baseline value.
Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Change in Tricuspid Annular Plane Systolic Excursion During Follow-up
Lasso di tempo: Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Tricuspid annular plane systolic excursion (TAPSE) will be assessed by transthoracic echocardiography and expressed in millimeters (mm). TAPSE will be measured preoperatively and reassessed at 3, 6, and 12 months after cardiac surgery. Changes at each follow-up time point will be evaluated relative to the preoperative baseline value.
Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Presence of Paradoxical Septal Motion During Follow-up
Lasso di tempo: Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Interventricular septal motion will be assessed by transthoracic echocardiography and classified according to the presence or absence of paradoxical septal motion (PSM). PSM status will be recorded preoperatively and reassessed at 3, 6, and 12 months after cardiac surgery to evaluate its postoperative evolution.
Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Change in TAPSE/sPAP Ratio During Follow-up
Lasso di tempo: Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
The ratio of tricuspid annular plane systolic excursion to systolic pulmonary artery pressure (TAPSE/sPAP), an echocardiographic index of right ventricular-pulmonary arterial coupling, will be assessed by transthoracic echocardiography and expressed in mm/mmHg. The TAPSE/sPAP ratio will be measured preoperatively and reassessed at 3, 6, and 12 months after cardiac surgery. Changes at each follow-up time point will be evaluated relative to the preoperative baseline value.
Preoperative baseline and 3, 6, and 12 months after index cardiac surgery.
Correlation Between Left Ventricular Global Longitudinal Strain and Pulmonary Capillary Wedge Pressure
Lasso di tempo: During index cardiac surgery at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass.
Left ventricular global longitudinal strain (LV GLS) will be assessed by speckle-tracking transthoracic echocardiography and expressed as a percentage (%). Pulmonary capillary wedge pressure (PCWP) will be measured invasively using a Swan-Ganz catheter and expressed in mmHg. Both measurements will be obtained at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass. The correlation between LV GLS and PCWP will be assessed at each time point using Pearson's or Spearman's correlation coefficient, as appropriate.
During index cardiac surgery at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass.
Correlation Between Left Ventricular Global Work Index and Pulmonary Capillary Wedge Pressure
Lasso di tempo: During index cardiac surgery at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass.
Left ventricular Global Work Index (GWI) will be assessed using non-invasive pressure-strain loop analysis and expressed in mmHg%. Pulmonary capillary wedge pressure (PCWP) will be measured invasively using a Swan-Ganz catheter and expressed in mmHg. Both measurements will be obtained at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass. The correlation between GWI and PCWP will be assessed at each time point using Pearson's or Spearman's correlation coefficient, as appropriate.
During index cardiac surgery at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass.
Correlation Between Left Ventricular Global Constructive Work and Pulmonary Capillary Wedge Pressure
Lasso di tempo: During index cardiac surgery at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass.
Left ventricular Global Constructive Work (GCW) will be assessed using non-invasive pressure-strain loop analysis and expressed in mmHg%. Pulmonary capillary wedge pressure (PCWP) will be measured invasively using a Swan-Ganz catheter and expressed in mmHg. Both measurements will be obtained at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass. The correlation between GCW and PCWP will be assessed at each time point using Pearson's or Spearman's correlation coefficient, as appropriate.
During index cardiac surgery at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass.
Correlation Between Left Ventricular Global Wasted Work and Pulmonary Capillary Wedge Pressure
Lasso di tempo: During index cardiac surgery at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass.
Left ventricular Global Wasted Work (GWW) will be assessed using non-invasive pressure-strain loop analysis and expressed in mmHg%. Pulmonary capillary wedge pressure (PCWP) will be measured invasively using a Swan-Ganz catheter and expressed in mmHg. Both measurements will be obtained at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass. The correlation between GWW and PCWP will be assessed at each time point using Pearson's or Spearman's correlation coefficient, as appropriate.
During index cardiac surgery at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass.
Correlation Between Left Ventricular Global Work Efficiency and Pulmonary Capillary Wedge Pressure
Lasso di tempo: During index cardiac surgery at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass.
Left ventricular Global Work Efficiency (GWE) will be assessed using non-invasive pressure-strain loop analysis and expressed as a percentage (%). Pulmonary capillary wedge pressure (PCWP) will be measured invasively using a Swan-Ganz catheter and expressed in mmHg. Both measurements will be obtained at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass. The correlation between GWE and PCWP will be assessed at each time point using Pearson's or Spearman's correlation coefficient, as appropriate.
During index cardiac surgery at T1, after induction of anesthesia and before cardiopulmonary bypass, and at T2, after separation from cardiopulmonary bypass.
Correlation Between Preoperative Right Atrial Strain and Intraoperative Pulmonary Capillary Wedge Pressure
Lasso di tempo: Preoperative transthoracic echocardiography within 24 hours before surgery and intraoperative PCWP assessment at T1, after induction of anesthesia and before cardiopulmonary bypass.
Preoperative right atrial strain (RA strain) will be assessed by speckle-tracking transthoracic echocardiography and expressed as a percentage (%). Pulmonary capillary wedge pressure (PCWP) will be measured invasively using a Swan-Ganz catheter at T1 and expressed in mmHg. The correlation between preoperative RA strain and PCWP will be assessed using Pearson's or Spearman's correlation coefficient, as appropriate.
Preoperative transthoracic echocardiography within 24 hours before surgery and intraoperative PCWP assessment at T1, after induction of anesthesia and before cardiopulmonary bypass.
Correlation Between Preoperative Right Atrial Strain and Intraoperative Cardiac Index
Lasso di tempo: Preoperative transthoracic echocardiography within 24 hours before surgery and intraoperative cardiac index assessment at T1, after induction of anesthesia and before cardiopulmonary bypass.
Preoperative right atrial strain (RA strain) will be assessed by speckle-tracking transthoracic echocardiography and expressed as a percentage (%). Cardiac index (CI) will be measured invasively using a Swan-Ganz catheter at T1 and expressed in L/min/m². The correlation between preoperative RA strain and CI will be assessed using Pearson's or Spearman's correlation coefficient, as appropriate.
Preoperative transthoracic echocardiography within 24 hours before surgery and intraoperative cardiac index assessment at T1, after induction of anesthesia and before cardiopulmonary bypass.
Correlation Between Preoperative Right Ventricular Free-Wall Strain and Intraoperative Pulmonary Capillary Wedge Pressure
Lasso di tempo: Preoperative transthoracic echocardiography within 24 hours before surgery and intraoperative PCWP assessment at T1, after induction of anesthesia and before cardiopulmonary bypass.
Preoperative right ventricular free-wall strain (RV FWS) will be assessed by speckle-tracking transthoracic echocardiography and expressed as a percentage (%). Pulmonary capillary wedge pressure (PCWP) will be measured invasively using a Swan-Ganz catheter at T1 and expressed in mmHg. The correlation between preoperative RV FWS and PCWP will be assessed using Pearson's or Spearman's correlation coefficient, as appropriate.
Preoperative transthoracic echocardiography within 24 hours before surgery and intraoperative PCWP assessment at T1, after induction of anesthesia and before cardiopulmonary bypass.
Correlation Between Preoperative Right Ventricular Free-Wall Strain and Intraoperative Cardiac Index
Lasso di tempo: Preoperative transthoracic echocardiography within 24 hours before surgery and intraoperative cardiac index assessment at T1, after induction of anesthesia and before cardiopulmonary bypass.
Preoperative right ventricular free-wall strain (RV FWS) will be assessed by speckle-tracking transthoracic echocardiography and expressed as a percentage (%). Cardiac index (CI) will be measured invasively using a Swan-Ganz catheter at T1 and expressed in L/min/m². The correlation between preoperative RV FWS and CI will be assessed using Pearson's or Spearman's correlation coefficient, as appropriate.
Preoperative transthoracic echocardiography within 24 hours before surgery and intraoperative cardiac index assessment at T1, after induction of anesthesia and before cardiopulmonary bypass.
Correlation Between Preoperative TAPSE/sPAP Ratio and Intraoperative Pulmonary Capillary Wedge Pressure
Lasso di tempo: Preoperative transthoracic echocardiography within 24 hours before surgery and intraoperative PCWP assessment at T1, after induction of anesthesia and before cardiopulmonary bypass.
The preoperative TAPSE/sPAP ratio will be assessed by transthoracic echocardiography and expressed in mm/mmHg. Pulmonary capillary wedge pressure (PCWP) will be measured invasively using a Swan-Ganz catheter at T1 and expressed in mmHg. The correlation between the preoperative TAPSE/sPAP ratio and PCWP will be assessed using Pearson's or Spearman's correlation coefficient, as appropriate.
Preoperative transthoracic echocardiography within 24 hours before surgery and intraoperative PCWP assessment at T1, after induction of anesthesia and before cardiopulmonary bypass.
Correlation Between Preoperative TAPSE/sPAP Ratio and Intraoperative Cardiac Index
Lasso di tempo: Preoperative transthoracic echocardiography within 24 hours before surgery and intraoperative cardiac index assessment at T1, after induction of anesthesia and before cardiopulmonary bypass.
The preoperative TAPSE/sPAP ratio will be assessed by transthoracic echocardiography and expressed in mm/mmHg. Cardiac index (CI) will be measured invasively using a Swan-Ganz catheter at T1 and expressed in L/min/m². The correlation between the preoperative TAPSE/sPAP ratio and CI will be assessed using Pearson's or Spearman's correlation coefficient, as appropriate.
Preoperative transthoracic echocardiography within 24 hours before surgery and intraoperative cardiac index assessment at T1, after induction of anesthesia and before cardiopulmonary bypass.
Correlation Between Preoperative E/LA Strain Ratio and Intraoperative Pulmonary Capillary Wedge Pressure
Lasso di tempo: Preoperative transthoracic echocardiography within 24 hours before surgery and intraoperative PCWP assessment at T1, after induction of anesthesia and before cardiopulmonary bypass.
The preoperative E/LA strain ratio will be calculated as the ratio of early diastolic transmitral flow velocity (E), measured by pulsed-wave Doppler echocardiography and expressed in cm/s, to left atrial strain, measured by speckle-tracking transthoracic echocardiography and expressed as a percentage (%). The E/LA strain ratio will be expressed in cm/s/%. Pulmonary capillary wedge pressure (PCWP) will be measured invasively using a Swan-Ganz catheter at T1 and expressed in mmHg. The correlation between the preoperative E/LA strain ratio and intraoperative PCWP will be assessed using Pearson's or Spearman's correlation coefficient, as appropriate.
Preoperative transthoracic echocardiography within 24 hours before surgery and intraoperative PCWP assessment at T1, after induction of anesthesia and before cardiopulmonary bypass.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Sponsor

L'organizzazione o la persona che avvia lo studio e che ha autorità e controllo sullo studio.
AHEPA University Hospital

Investigatori

Investigatori

Un ricercatore coinvolto in uno studio clinico. I termini correlati includono il ricercatore principale del sito, il ricercatore secondario del sito, il presidente dello studio, il direttore dello studio e il ricercatore principale dello studio.
  • Cattedra di studio: Vasileios Kamperidis, Assistant Professor, 1st Department of Cardiology, School of Medicine, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece
  • Direttore dello studio: Despoina Sarridou, Associate Professor, Department of Anesthesiology, AHEPA University Hospital, Aristotle University of Thessaloniki
  • Direttore dello studio: Helena Argiriadou, Professor, Department of Anesthesiology and Intensive Care, AHEPA University Hospital, Aristotle University of Thessaloniki
  • Direttore dello studio: Antonios Ziakas, Professor, 1st Department of Cardiology, School of Medicine, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece
  • Investigatore principale: Christos Mantzios, Cardiology Resident, MD, MSc, 1st Department of Cardiology, School of Medicine, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

Inizio studio

La data effettiva in cui il primo partecipante è stato arruolato in uno studio clinico. La data di inizio dello studio "prevista" è la data che i ricercatori pensano sarà la data di inizio dello studio.
19 gennaio 2026

Completamento primario (Stimato)

Completamento primario

La data in cui l'ultimo partecipante a uno studio clinico è stato esaminato o ha ricevuto un intervento per raccogliere i dati finali per la misura dell'esito primario. Il fatto che lo studio clinico sia terminato secondo il protocollo o sia stato interrotto non influisce su questa data. Per gli studi clinici con più di una misura di esito primario con diverse date di completamento, questo termine si riferisce alla data in cui la raccolta dei dati è completata per tutte le misure di esito primario. La data di completamento principale "prevista" è la data che i ricercatori ritengono sarà la data di completamento principale per lo studio.
1 novembre 2026

Completamento dello studio (Stimato)

Completamento dello studio

La data in cui l'ultimo partecipante a uno studio clinico è stato esaminato o ha ricevuto un intervento/trattamento per raccogliere i dati finali per le misure di esito primarie, le misure di esito secondarie e gli eventi avversi (ovvero l'ultima visita dell'ultimo partecipante). La data di completamento dello studio "prevista" è la data che i ricercatori ritengono sarà la data di completamento dello studio.
1 novembre 2027

Date di iscrizione allo studio

Primo inviato

Primo inviato

La data in cui lo sponsor o il ricercatore dello studio ha inviato per la prima volta un record di studio a ClinicalTrials.gov. In genere c'è un ritardo di alcuni giorni tra la prima data di invio e la disponibilità del record su ClinicalTrials.gov (la prima data di invio).
10 agosto 2026

Primo inviato che soddisfa i criteri di controllo qualità

Primo inviato che soddisfa i criteri di controllo qualità

La data in cui lo sponsor dello studio o il ricercatore invia per la prima volta un record di studio che è coerente con i criteri di revisione del controllo di qualità (QC) della National Library of Medicine (NLM). Lo sponsor o lo sperimentatore potrebbe dover rivedere e inviare un record di studio una o più volte prima che i criteri di revisione QC di NLM siano soddisfatti. È responsabilità dello sponsor o dello sperimentatore garantire che il record dello studio sia coerente con i criteri di revisione QC NLM.
13 agosto 2026

Primo Inserito (Effettivo)

Primo Inserito

La data in cui il record dello studio è stato disponibile per la prima volta su ClinicalTrials.gov dopo la conclusione della revisione del controllo di qualità (QC) della National Library of Medicine (NLM). In genere c'è un ritardo di alcuni giorni tra la data in cui lo sponsor dello studio o lo sperimentatore ha presentato il record dello studio e la prima data pubblicata.
18 agosto 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

Ultimo aggiornamento pubblicato

La data più recente in cui le modifiche al record di uno studio sono state rese disponibili su ClinicalTrials.gov. Potrebbe esserci un ritardo tra il momento in cui le modifiche sono state inviate a ClinicalTrials.gov dallo sponsor o dallo sperimentatore dello studio (data di invio dell'ultimo aggiornamento) e la data di pubblicazione dell'ultimo aggiornamento.
19 agosto 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

Ultimo aggiornamento inviato che soddisfa i criteri QC

La data più recente in cui lo sponsor dello studio o il ricercatore ha presentato modifiche a un record di studio che sono coerenti con i criteri di revisione del controllo di qualità (QC) della National Library of Medicine (NLM). È responsabilità dello sponsor o dello sperimentatore garantire che il record dello studio sia coerente con i criteri di revisione QC NLM.
18 agosto 2026

Ultimo verificato

Ultimo verificato

La data più recente in cui lo sponsor dello studio o il ricercatore ha confermato che le informazioni su uno studio clinico su ClinicalTrials.gov sono accurate e aggiornate. Se uno studio con stato di reclutamento di reclutamento; non ancora reclutamento; o attivo, non reclutamento non è stato confermato negli ultimi 2 anni, lo stato di reclutamento dello studio viene mostrato come sconosciuto.
1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

Altri numeri di identificazione dello studio

Identificatori o numeri ID diversi dal numero NCT assegnati a uno studio clinico dallo sponsor, dai finanziatori o da altri dello studio. Questi numeri possono includere identificatori univoci di altri registri di sperimentazione e numeri di sovvenzioni del National Institutes of Health.
  • SHAPE

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant-level data will not be shared with other researchers.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Impostazioni dei cookie

Utilizziamo i cookie per assicurarci di darti la migliore esperienza sul nostro sito web. Per maggiori dettagli leggi attentamente la nostra Informativa sulla privacy e sui cookie. ...>>>Puoi modificare le tue preferenze o revocare il tuo consenso in qualsiasi momento eliminando i cookie dal tuo sito web o computer come descritto nella policy. Accettalo e scegli le tue preferenze spuntando le caselle corrispondenti nella sezione "Gestisci impostazioni" di seguito. Leggi attentamente i nostri Termini di servizio prima di procedere con l'utilizzo di qualsiasi parte di questo sito web.
«Gestisci impostazioni